Overview

Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHD

Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This open label, flexible-dose study evaluating the safety and efficacy of SPN-812 administered with psychostimulants in children and adolescents (6 to 17 years of age) with Attention-Deficit/Hyperactivity Disorder (ADHD).
Phase:
Phase 4
Details
Lead Sponsor:
Supernus Pharmaceuticals, Inc.